登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRixv，2月29日，The Effects of "Fangcang, Huoshenshan, and Leishenshan" Makeshift Hospitals and Temperature on the Mortality of COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-01

  • The Effects of "Fangcang, Huoshenshan, and Leishenshan" Makeshift Hospitals and Temperature on the Mortality of COVID-19

    Yuwen Cai, Tianlun Huang Sr., Xin Liu Sr., Gaosi Xu Sr.

    doi: https://doi.org/10.1101/2020.02.26.20028472

    Abstract

    Background: In December 2019, a novel coronavirus disease (COVID-19) broke out in Wuhan, China, however, the factors affecting the mortality remain unclear. Methods: A cross-sectional study based on 32 days (from January 21, 2020 to February 21, 2020) of data that were shared by China National Health Commission and China Weather Net. We compared the difference in the growth rate of confirmed cases and the mortality of confirmed cases and severe cases before and after Fangcang, Huoshenshan, and Leishenshan makeshift hospitals (MSHs) were put into use. We also studied whether air temperature (AT) could affect the above outcomes of COVID-19 patients.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.02.26.20028472v1
77浏览量
原文链接
相关报告

  • 《MedRxiv，3月6日，The Effects of "Fangcang, Huoshenshan, and Leishenshan" Makeshift Hospitals and Temperature on the Mortality of COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-07
    • The Effects of "Fangcang, Huoshenshan, and Leishenshan" Makeshift Hospitals and Temperature on the Mortality of COVID-19 Yuwen Cai, Tianlun Huang Sr., Xin Liu Sr., Gaosi Xu Sr. doi: https://doi.org/10.1101/2020.02.26.20028472 Abstract Background In December 2019, a novel coronavirus disease (COVID-19) broke out in Wuhan, China, however, the factors affecting the mortality remain unclear. Methods Thirty-two days of data that were shared by China National Health Commission and China Weather Net were collected using standard forms. The difference in the mortality of confirmed and severe cases before and after the use of Fangcang, Huoshenshan, and Leishenshan makeshift hospitals (MSHs) was tested using Mann-Whitney U test. We also studied whether air temperature (AT) could affect the above outcomes of COVID-19 cases by performing Spearman analysis. Results The mortality of confirmed cases was significantly decreased both in Wuhan (U = 1, P < 0.001) and Hubei (U = 0, P < 0.001), while in non-Hubei regions, as a contrast, the mortality of confirmed cases remained unchanged (U = 40, P = 0.139). However, another eight days later, changes in the mortality in non-Hubei regions also became significant (U = 73, P = 0.039). Mortality of confirmed cases was found to be significantly correlated with temperature both in Wuhan (r = -0.441, P = 0.012) and Hubei (r = -0.440, P = 0.012). Conclusions Our findings indicated that both the use of MSHs and the rise of AT were beneficial to the survival of COVID-19 cases. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    125浏览量
    原文链接

  • 《MedRixv，2月29日，Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-01
    • Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction Xiaoyan Liu, Zhe Li, Shuai Liu, Zhanghua Chen, Zhiyao Zhao, Yi-you Huang, Qingling Zhang, Jun Wang, Yinyi Shi, Yanhui Xu, Jing Sun, Huifang Xian, Rongli Fang, Fan Bai, Changxing Ou, Bei Xiong, Andrew M Lew, Jun Cui, Hui Huang, Jincun Zhao, Xuechuan Hong, Yuxia Zhang, Fulin Zhou, Hai-Bin Luo doi: https://doi.org/10.1101/2020.02.27.20027557 Abstract The human coronavirus HCoV-19 infection can cause acute respiratory distress syndrome (ARDS), hypercoagulability, hypertension, extrapulmonary multiorgan dysfunction. Effective antiviral and anti-coagulation agents with safe clinical profiles are urgently needed to improve the overall prognosis. We screened an FDA approved drug library and found that an anticoagulant agent dipyridamole (DIP) suppressed HCoV-19 replication at an EC50 of 100 nM in vitro. It also elicited potent type I interferon responses and ameliorated lung pathology in a viral pneumonia model. In analysis of twelve HCoV-19 infected patients with prophylactic anti-coagulation therapy, we found that DIP supplementation was associated with significantly increased platelet and lymphocyte counts and decreased D-dimer levels in comparison to control patients. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    30浏览量
    原文链接